BlackRock’s Benitec Biopharma BNTC Stock Holding History

BlackRock’s Portfolio BNTC Stock Details BNTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$12.6M	Buy	1,185,741 +193,394	+19%	+$2.24M	﹤0.01%	3351
2025 Q4	$13.4M	Buy	992,347 +46,832	+5%	+$648K	﹤0.01%	3321
2025 Q3	$13.3M	Buy	945,515 +226,825	+32%	+$2.89M	﹤0.01%	3309
2025 Q2	$8.41M	Buy	718,690 +534,264	+290%	+$7.47M	﹤0.01%	3498
2025 Q1	$2.4M	Buy	184,426 +10,673	+6%	+$129K	﹤0.01%	3937
2024 Q4	$2.19M	Buy	173,753 +145,515	+515%	+$1.57M	﹤0.01%	4005
2024 Q3	$260K	Buy	28,238 +234	+0.8%	+$2.09K	﹤0.01%	4471
2024 Q2	$196K	Buy	+28,004	New	+$207K	﹤0.01%	4553
2022 Q2	–	Sell	-1,150	Closed	-$46K	–	5856
2022 Q1	$46K	Sell	1,150 -56	-5%	-$2.32K	﹤0.01%	5423
2021 Q4	$53K	Buy	1,206 +31	+3%	+$1.73K	﹤0.01%	5390
2021 Q3	$71K	Sell	1,175 -231	-16%	-$15.2K	﹤0.01%	5227
2021 Q2	$101K	Buy	+1,406	New	+$110K	﹤0.01%	5042

Other funds holding BNTC

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

IAM

Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

BlackRock's BNTC Position: Q1 2026 in Review

BlackRock increased its Benitec Biopharma (BNTC) stake by 19% in Q1 2026, buying an estimated $2.24M and bringing the position to 1,185,741 shares worth $12.6M. The position accounts for ﹤0.01% of the portfolio, ranked #3351.

BlackRock first reported a position in BNTC in Q2 2021 and has held it in 12 quarters since. The position peaked at $13.4M in Q4 2025. 88 funds tracked by Wall St. Rank hold BNTC as of Q1 2026.

BlackRock held 1,185,741 shares of Benitec Biopharma worth $12.6M as of Q1 2026.
BlackRock bought 193,394 Benitec Biopharma shares in Q1 2026, an estimated $2.24M.
Benitec Biopharma made up ﹤0.01% of BlackRock's portfolio in Q1 2026, its #3351 holding.
BlackRock first reported a position in Benitec Biopharma in Q2 2021 and has held it in 12 quarters since.
BlackRock's Benitec Biopharma position peaked at $13.4M in Q4 2025.
88 funds tracked by Wall St. Rank held Benitec Biopharma as of Q1 2026.

Based on BlackRock's 13F filing for Q1 2026, filed 13 May 2026.